|
N = 346
|
IFNα-negative (n = 255)
|
IFNα-positivea (n = 91)
|
p-value
|
|---|
|
Age, yearsb
|
58 (18–81)
|
58 (21–82)
|
0.53
|
|
Female sexc
|
170 (67%)
|
64 (70%)
|
0.60
|
|
BMI, kg/m2b
|
25 (18–43)
|
26 (19–43)
|
0.22
|
|
Current smokerc
|
46 (18%)
|
25 (27%)
|
0.07
|
|
Autoantibody statusc
| | |
< 0.0001
|
|
RF-ACPA-
|
33 (13%)
|
3 (3%)
|
p < 0.05d
|
|
RF+ACPA-
|
23 (9%)
|
2 (2%)
|
ns
|
|
RF-ACPA+
|
52 (20%)
|
2 (2%)
|
p < 0.05d
|
|
RF+ACPA+
|
146 (57%)
|
84 (92%)
|
p < 0.05d
|
|
Disease activity day 1b
| | | |
|
CDAI
|
27.8 (7.8–68.7)
|
28.6 (10.1–68.4)
|
0.13
|
|
DAS28-CRP
|
5.1 (2.2–8.3)
|
5.1 (3.3–7.7)
|
0.38
|
|
DAS28-ESR
|
5.5 (2.6–8.7)
|
5.5 (3.3–8.2)
|
0.43
|
|
SJC-66
|
11 (1–42)
|
11 (2–38)
|
0.68
|
|
TJC-68
|
13 (0–49)
|
16 (2–62)
|
0.16
|
|
CRP, mg/L
|
14 (0.3–216)
|
8 (0.5–190)
|
0.16
|
|
ESR, mm/h
|
28 (2–115)
|
28 (4–108)
|
0.26
|
|
PGA, mm
|
59 (2–100)
|
56 (22–100)
|
0.59
|
|
Disease activity week 24b
| | | |
|
CDAI
|
3.4 (0–28.3)
|
3.5 (0–26.6)
|
0.47
|
|
DAS28-CRP
|
2.0 (1.1–4.8)
|
2.0 (1.0–5.0)
|
0.82
|
|
DAS28-ESR
|
2.3 (0–6.0)
|
2.2 (0–5.8)
|
0.91
|
|
SJC-66
|
0 (0–9)
|
0 (0–7)
|
0.88
|
|
TJC-68
|
1 (0–37)
|
2 (0–41)
|
0.22
|
|
CRP, mg/L
|
1 (0–39)
|
1 (0.1–15)
|
0.86
|
|
ESR, mm/h
|
8 (1–78)
|
8 (1–48)
|
0.52
|
|
PGA, mm
|
11 (0–78)
|
14 (0–92)
|
0.40
|
- BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, CDAI clinical disease activity index, DAS28 disease activity score 28 joints, SJC-66 swollen joint count, 66 joints, TJC-68 tender joint count, 68 joints, CRP C-reactive protein, ESR erythrocyte sedimentation rate, PGA patient global assessment
- aIFNα positivity defined as IFNα protein level above 136 fg/mL
- bMedian (range), Mann-Whitney U-test
- cn (%), Fisher’s exact test
- dp < 0.05 after post hoc step-down Bonferroni-Holm correction for multiple testing
